JAN 2 4 2018

A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1	SECTION 1. Section 329-16, Hawaii Revised Statutes, is		
2	amended by amending subsection (b) to read as follows:		
3	"(b) Any of the following substances, except those		
4	narcotic drugs listed in other schedules, whether produced		
5	directly or indirectly by extraction from substances of		
6	vegetable origin, or independently by means of chemical		
7	synthesis, or by combination of extraction and chemical		
8	synthesis:		
9	(1) Opium and opiate, and any salt, compound, derivative,		
10	or preparation of opium or opiate, excluding		
11	apomorphine, thebaine-derived butorphanol,		
12	dextrorphan, nalbuphine, nalmefene, naloxegol,		
13	naloxone, and naltrexone, and their respective salts,		
14	but including the following:		
15	(A) Raw opium;		
16	(B) Opium extracts;		
17	(C) Opium fluid;		
18	(D) Powdered opium;		

```
1
               (E)
                    Granulated opium;
 2
                    Codeine;
               (F)
 3
               (G)
                    Ethylmorphine;
 4
               (H)
                    Etorphine hydrochloride;
 5
               (I)
                    Hydrocodone;
 6
                    Hydromorphone;
               (J)
7
                    Metopon;
               (K)
8
               (上)
                    Morphine;
9
                    Oxycodone;
               (M)
10
                    Oxymorphone;
               (N)
11
               (O)
                    Thebaine;
12
                    Dihydroetorphine;
               (P)
13
               (Q)
                    Oripavine; and
14
                    Tincture of opium;"
               (R)
              Any salt, compound, isomer, derivative, or preparation
15
          (2)
16
               thereof which is chemically equivalent or identical
17
              with any of the substances referred to in paragraph
18
               (1), but not including the isoquinoline alkaloids of
19
              opium;
20
         (3)
              Opium poppy and poppy straw;
         (4)
21
              Coca leaves and any salt, compound, derivative, or
22
              preparation of coca leaves, and any salt, compound,
```

1 derivative, or preparation thereof which is chemically 2 equivalent or identical with any of these substances, 3 but not including decocanized coca leaves or 4 extractions which do not contain cocaine or ecgonine; 5 cocaine or any salt or isomer thereof; and 6 (5) Concentrate of poppy straw (the crude extract of poppy 7 straw in either liquid, solid, or powder form that 8 contains the phenanthrene alkaloids of the opium 9 ". (yqqoq 10 SECTION 2. Section 329-38, Hawaii Revised Statutes, is 11 amended by amending subsection (h) to read as follows: 12 The effectiveness of a prescription for the purposes 13 of this section shall be determined as follows: 14 (1)A prescription for a controlled substance shall be 15 issued for a legitimate medical purpose by an 16 individual practitioner acting in the usual course of 17 the practitioner's professional practice. 18 responsibility for the proper prescribing and 19 dispensing of controlled substances shall be upon the 20 prescribing practitioner, but a corresponding 21 responsibility shall rest with the pharmacist who 22 fills the prescription. An order purporting to be a

1		prescription issued not in the usual course of
2		professional treatment or for legitimate and
3		authorized research shall not be deemed a prescription
4		within the meaning and intent of this section, and the
5	-	person who knowingly fills such a purported
6		prescription, as well as the person who issues the
7		prescription, shall be subject to the penalties
8		provided for violations of this chapter;
9	(2)	A prescription may not be issued to allow an
10		individual practitioner to obtain controlled
11		substances for supplying the individual practitioner
12		for the purpose of general dispensing to patients;
13	[(3)	A prescription may not be issued for the dispensing
14		of narcotic drugs listed in any schedule for the
15		purpose of "medically managed withdrawal", also known
16		as "detoxification treatment", or "maintenance
17		treatment" except as follows:
18		(A) The administering or dispensing directly (but not
19		prescribing) of narcotic drugs listed in any
20		schedule to a narcotic drug-dependent person for
21		"medically managed withdrawal", also known as
22		"detoxification treatment" or "maintenance

1		treatment" shall be deemed to be "in the course
2		of a practitioner's professional practice or
3		research" so long as the practitioner is
4		registered separately with the department and the
5		federal Drug Enforcement Agency as required by
6		section 329-32(e) and complies with Title 21 Code
7		of Federal Regulations section 823(g) and any
8		other federal or state regulatory standards
9		relating to treatment qualification, security,
10		records, and unsupervised use of drugs; and
11		(B) Nothing in this section shall prohibit a
12		physician or authorized hospital staff from
13		administering or dispensing, but not prescribing,
14		narcotic drugs in a hospital to maintain or
15		detoxify a person-as an incidental adjunct to
16		medical or surgical treatment of conditions other
17		than addiction;
18	(3)	A prescription may not be issued for "medically
19		managed withdrawal", also known as "detoxification
20		treatment" or "maintenance treatment", unless the
21		prescription is for a schedule III, IV, or V narcotic
22		drug approved by the Food and Drug Administration

1		spec	cifically for use in maintenance or detoxification
2		trea	atment and the practitioner is in compliance with
3		titl	e 21 Code of Federal Regulations section 1301.28,
4		the	registration requirements of section 329-32(e),
5		and	any other federal or state regulatory standards
6		<u>rela</u>	ating to treatment qualification, security,
7		reco	ords, and unsupervised use of drugs;
8	(4)	A pr	ractitioner may administer or dispense directly
9		(but	not prescribe) a narcotic drug listed in any
10		sche	edule to a narcotic dependent person for the
11		purp	oose of maintenance or detoxification treatment if
12		the	practitioner meets both of the following
13		cond	ditions:
14		(A)	The practitioner is separately registered with
15			the Drug Enforcement Administration as a narcotic
16			treatment program.
17		(B)	The practitioner is in compliance with Drug
18			Enforcement Administration regulations regarding
19			treatment qualifications, security, records, and
20			unsupervised use of the drugs pursuant to this
21			chapter;

1	(5)	Nothing in this section shall prohibit a physician who
2		is not specifically registered to conduct a narcotic
3		treatment program from administering (but not
4		prescribing) narcotic drugs to a person for the
5	. .	purpose of relieving acute withdrawal symptoms when
6		necessary while arrangements are being made for
7		referral for treatment. Not more than one day's
8		medication may be administered to the person or for
9		the person's use at one time. Such emergency
10		treatment may be carried out for not more than three
11		days and may not be renewed or extended;
12	(6)	This section is not intended to impose any limitations
13		on a physician or authorized hospital staff to
14		administer or dispense narcotic drugs in a hospital to
15		maintain or detoxify a person as an incidental adjunct
16		to medical or surgical treatment of conditions other
17		than addiction, or to administer or dispense narcotic
18		drugs to persons with intractable pain in which no
19		relief or cure is possible or none has been found
20		after reasonable efforts;
21	(7)	A practitioner may administer or dispense (including
22		prescribe) any schedule III, IV, or V narcotic drug

1		approved by the Food and Drug Administration
2		specifically for use in maintenance or detoxification
3		treatment to a narcotic dependent person if the
4		practitioner complies with the requirements of title
5		21 Code of Federal Regulations section 1301.28, the
6		registration and any requirements of section 329-
7		32(e), and any other federal or state regulatory
8		standards relating to treatment qualification,
9		security, records, and unsupervised use of drugs;
10	[(4)]	(8) An individual practitioner shall not prescribe or
11		dispense a substance included in schedule II, III, IV,
12		or V for that individual practitioner's personal use,
13		except in a medical emergency; and
14	[(5)]	(9) A pharmacist shall not dispense a substance
15		included in schedule II, III, IV, or V for the
16		pharmacist's personal use."
17	SECT	ION 3. Statutory material to be repealed is bracketed
18	and stric	ken. New statutory material is underscored.
19	SECT	ION 4. This Act shall take effect upon its approval.
20		
21		INTRODUCED BY:
22		BY REQUEST

Report Title:

Uniform Controlled Substances Act

Description:

Updates chapter 329, Hawaii Revised Statutes, as follows: amends sections 329-16 and 329-38(h) to be consistent with federal law, by allowing prescribing authorization of drugs which include buprenorphine and naloxone to patients undergoing "medically managed withdrawal", also known as "detoxification treatment" and "maintenance treatment" by practitioners who are properly registered.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

JUSTIFICATION SHEET

DEPARTMENT:

Public Safety

TITLE:

A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

PURPOSE:

Update chapter 329, Hawaii Revised Statutes (HRS), as follows: amend sections 329-16 and 329-38(h), HRS, to be consistent with federal law by allowing prescribing authorization of drugs including buprenorphine to patients undergoing "medically managed withdrawal", also known as "detoxification treatment" and "maintenance treatment" by practitioners who are properly registered.

MEANS:

Amend sections 329-16(b) and 329-38(h), HRS.

JUSTIFICATION:

Proposed amendments to chapter 329, HRS, will:

- (1) Amend section 329-16(b), schedule II, to list exclusions as provided for under title 21 Code of Federal Regulations (CFR) section 1308.12. This amendment excludes naloxone, as well as other opiate-based drugs, from schedule II, which would allow practitioners to prescribe them to patients undergoing "medically managed withdrawal", also known as "detoxification treatment" and "maintenance treatment."
- (2) Amend section 329-38(h), HRS, to allow prescribing of schedule III, IV, and V drugs as provided for under title 21 CFR sections 1306.04 and 1306.07. This amendment clarifies that buprenorphine, a schedule III drug, may be prescribed to patients undergoing "medically managed withdrawal", also known as "detoxification treatment" and "maintenance treatment" by practitioners who are registered separately with the department and the federal Drug Enforcement Administration as required by section 329-32(e), HRS, and comply with title 21 CFR section 1301.28. This amendment provides practitioners with

prescribing authority for buprenorphine consistent the federal Drug Abuse Treatment Act of 2000 (DATA 2000).

Impact on the public: This bill updates chapter 329 to be consistent with federal law, facilitates accessibility of buprenorphine and naloxone medication for substance abuse treatment by practitioners.

Impact on the department and other agencies:
These proposed amendments would assist the
Department's Narcotics Enforcement Division in
its regulation of the Uniform Controlled
Substances Act and maintaining its law
enforcement, controlled substance
registration, Hawaii Prescription Database
Monitoring Program (HI-PDMP) and other
services it provides to prevent diversion and
drug abuse in the community.

GENERAL FUND:

None.

OTHER FUNDS:

None.

OTHER AFFECTED

AGENCIES:

State Of Hawaii, Department of Health, Alcohol

and Drug Abuse Division.

Federal, State, and County law enforcement.

EFFECTIVE DATE:

Upon approval.